secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0000950170-24-024346
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint names Ramiro Ribeiro as Chief Medical Officer, replaces Dario Paggiarino
--------------------------------------------------------------------------------

- Ramiro Ribeiro appointed CMO effective March 1, 2024; succeeds Dario Paggiarino who leaves March 31.
- Ribeiro joins from Apellis, where he led global Phase 3 GA program and FDA approval of SYFOVRE.
- Company on track to report Phase 2 PAVIA topline data for EYP-1901 in NPDR in Q2 2024.
- Initiation of Phase 3 LUGANO trial for EYP-1901 in wet AMD expected in second half 2024.
- Board granted 125,000 stock options as inducement award to Ribeiro under Nasdaq Rule 5635(c)(4).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024024346/0000950170-24-024346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024024346/eypt-20240304.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-024346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer